Skip to main content
. Author manuscript; available in PMC: 2021 Apr 2.
Published in final edited form as: Clin Rev Allergy Immunol. 2020 Nov 13;60(1):31–45. doi: 10.1007/s12016-020-08823-4

Fig. 1.

Fig. 1

Biologics targeting IL-23/IL-17 axis in rheumatic diseases. Specific blocking antibodies and small molecules targeting IL-23/IL-17 axis which are currently used in clinical practice or still under development are depicted (MQ: macrophages; DC: dendritic cells)